[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1996

Use of the Ganciclovir Implant in the Treatment of Recurrent Cytomegalovirus Retinitis

Author Affiliations

From the Doheny Eye Institute, Department of Ophthalmology, University of Southern California School of Medicine, Los Angeles.

Arch Ophthalmol. 1996;114(7):815-820. doi:10.1001/archopht.1996.01100140029003
Abstract

Objective:  To evaluate the efficacy of the ganciclovir implant in the treatment of recurrent cytomegalovirus (CMV) retinitis.

Methods:  Patients with acquired immunodeficiency syndrome and recurrent CMV retinitis were evaluated for entry into the study. A ganciclovir implant was inserted in 91 eyes of 70 patients between October 1992 and October 1995. The efficacy of the implant and visual results were retrospectively reviewed.

Results:  Fifty-three (76%) of 70 eyes had inactive CMV retinitis 1 month postoperatively (positive initial response). Twenty-one eyes of 19 patients had less than 1 month of follow-up. Nineteen (36%) of 53 eyes developed recurrent CMV retinitis. The median time to recurrence for those patients with a positive initial response was 7 months. Forty-eight (84%) of57 patients with follow-up longer than 1 month after implant insertion in the first eye received systemic anti-CMV medication during the study. The cumulative risk for developing a retinal detachment was 23% at 6 months following implant insertion. Other complications included vitreous hemorrhage, hyphema, and suprachoroidal implantation of the device.

Conclusion:  The ganciclovir implant is effective as an adjunct to continued systemic therapy in those patients with recurrent CMV retinitis.

References
1.
Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY.  Acquired immune deficiency syndrome: ocular manifestations . Ophthalmology . 1983;90:859-873.Article
2.
Palestine AG, Rodrigues MM, Macher AM, et al.  Ophthalmic involvement in acquired immunodeficiency syndrome . Ophthalmology . 1984;91:1092-1099.Article
3.
Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY.  Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease . Ophthalmology . 1985;92:472-484.Article
4.
Jabs DA, Green WR, Fox R, Folk BF, Bartlett JG.  Ocular manifestations of acquired immune deficiency syndrome . Ophthalmology . 1989;96:1092-1099.Article
5.
Gross JG, Bozette SA, Mathews WC, et al.  Longitudinal study of cytomegalvirus retinitis in acquired immune deficiency syndrome . Ophthalmology . 1990;97:681-686.Article
6.
Orellana J, Teich SA, Friedman AH, Lerebours F, Winterkonn J, Mildvan D.  Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U) . Ophthalmology . 1987;94:831-838.Article
7.
Jabs DA, Newman C, de Bustros S, Polk BF.  Treatment of cytomegalovirus retinitis with ganciclovir . Ophthalmology . 1987;94:824-830.Article
8.
Holland GN, Sidikaro Y, Kreiger AE, et al.  Treatment of cytomegalovirus retinopathy with ganciclovir . Ophthalmology . 1987;94:815-823.Article
9.
Henderly DE, Freeman WR, Causey DM, Rao NA.  Cytomegalovirus retinitis and response to therapy with ganciclovir . Ophthalmology . 1987;94:425-434.Article
10.
Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ,  UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome . Arch Ophthalmol . 1989;107:1759-1766.Article
11.
LeHoang P, Girard B, Robinet M, et al.  Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome . Ophthalmology . 1989;96:865-873.Article
12.
Palestine AG, Polis MA, DeSmet MD, et al.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS . Ann Intern Med . 1991;115:665-673.Article
13.
Holland GN, Shuler JD.  Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients . Arch Ophthalmol . 1992;110:1435-1442.Article
14.
Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.  Foscarnet-Gancicloivir Cytomegalovirus Retinitis Trial, 4: visual outcomes . Ophthalmology . 1994;101:1250-1261.Article
15.
Kuppermann BD, Flores-Aguilar M, Quiceno JI, Rickman LS, Freeman WR.  Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome . Arch Ophthalmol . 1993;111:1359-1366.Article
16.
Henry K, Cantrill H, Fletcher C.  Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS . Am J Ophthalmol . 1987;103:17-23.
17.
Ussery FM III, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ.  Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis . Ophthalmology . 1988;95:640-648.Article
18.
Cantrill HL, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH.  Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results . Ophthalmology . 1989;96:367-374.Article
19.
Diaz-Llopis M, Chipont E, Sanchez S, Espana E, Navea A, Menezo JL.  Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome . Am J Ophthalmol . 1992;114:742-747.
20.
Heinemann M-H.  Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy . Arch Ophthalmol . 1989;107:1767-1772.Article
21.
Sanborn GE, Anand R, Torti RE, et al.  Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinopathy: use of an intravitreal device . Arch Ophthalmol . 1992;110:188-195.Article
22.
Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P.  Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir . Arch Ophthalmol . 1993;111:223-227.Article
23.
Smith TJ, Pearson PA, Blandford DL, et al.  Intravitreal sustained-release ganciclovir . Arch Ophthalmol . 1992;110:255-258.Article
24.
Martin DF, Parks DJ, Mellow SD, et al.  Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant . Arch Ophthalmol . 1994;112:1531-1539.Article
25.
Freeman WR, Henderly DE, Wan WL, et al.  Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis . Am J Ophthalmol . 1986;103:527-536.
26.
Jabs DA, Enger C, Haller J, de Bustros S.  Retinal detachments in patients with cytomegalovirus retinitis . Arch Ophthalmol . 1991;109:794-799.Article
27.
Sidikaro Y, Silver L, Holland GN, Kreiger AE.  Rhegmatogenous retinal detachments in patients with AIDS and necrotizing retinal infections . Ophthalmology . 1991;98:129-135.Article
28.
Freeman WR, Friedberg DN, Berry C.  Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis . Am J Ophthalmol . 1993;116:713-720.
×